Get the latest Science News and Discoveries

AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging - EurekAlert!

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Related news:

First-in-class small molecule inhibitor designed with AI support shows promise against pancreatic cancer in preclinical studies - EurekAlert!

Insilico Medicine receives NMPA IND clearance for innovative oral candidate ISM8969/HT-001, the brain-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics - EurekAlert!

Eating less protein could slow aging, major review finds

« CXorf67 emerges as a potential precision oncology target across multiple cancer types - EurekAlert!

Highest-resolution images of the Sun reveal ubiquitous plasma vortices on its surface for the first time »